Literature DB >> 3035012

Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness.

H Quill, R H Schwartz.   

Abstract

Culture of normal inducer T cell clones with antigen and purified Ek beta:Ek alpha incorporated into planar lipid membranes resulted in specific T cell activation as determined by cell volume increase and IL 3 production. However, in contrast to results obtained with T cell hybridomas, antigen presentation by planar membranes did not induce measurable IL 2 production, and proliferative responses were not detected. Rather, recognition of only Ek beta:Ek alpha and antigen resulted in the specific induction of a long-lived state of proliferative nonresponsiveness to subsequent stimulation by conventional APC and antigen. Induction of nonresponsiveness required protein synthesis, and was not simply due to the absence of IL 2. The antigen-nonresponsive cells could respond to either PMA plus ionomycin or IL 2, and they expressed normal levels of surface antigen-receptor molecules. These results demonstrate that recognition by normal T cell clones of antigen and Ia molecules in the absence of other accessory cell molecules and signals results in a prolonged state of proliferative nonresponsiveness, possibly similar to a state of T cell tolerance in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035012

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  109 in total

Review 1.  Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?

Authors:  K Honey; S P Cobbold; H Waldmann
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

3.  Induction of T cell anergy by liposomes with incorporated major histocompatibility complex (MHC) II/peptide complexes.

Authors:  A J van Rensen; L S Taams; M C Grosfeld-Stulemeyer; W van Eden; D J Crommelin; M H Wauben
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

4.  Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation.

Authors:  A J van Rensen; M H Wauben; M C Grosfeld-Stulemeyer; W van Eden; D J Crommelin
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

5.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.

Authors:  David G Brooks; Philip A Arlen; Lianying Gao; Christina M R Kitchen; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

6.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Authors:  L A Turka; P S Linsley; H Lin; W Brady; J M Leiden; R Q Wei; M L Gibson; X G Zheng; S Myrdal; D Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

7.  "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.

Authors:  T F Gajewski; D W Lancki; R Stack; F W Fitch
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

8.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

Authors:  C D Gimmi; G J Freeman; J G Gribben; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

Review 10.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.